CD274 and plasma cell myeloma: revealed that both lenalidomide and pomalidomide have higher anti-myeloma efficacy toward dendritic cell vaccination in a MM mouse model when combined with PD-1 or PD-L1 blockade to inhibit immunosuppressive cells and restore effector cells (42, 43).